The invention describes anti-cancer therapies comprising using an MDM2 inhibitor in combination with a PD-1 antagonist and a LAG-3 antagonist, each as described herein.

The present invention relates to novel interferon-associated antigen binding proteins as well as nucleic acids and expression vectors encoding such interferon-associated antigen binding proteins for use in therapy, more particularly for use in treating hepatitis B virus (HBV) infection. The present invention also relates to pharmaceutical compositions comprising such interferon-associated antigen binding proteins or nucleic acids or expression vectors for use in therapy, more particularly for use in treating hepatitis B virus (HBV) infection. The present invention further provides methods of treatment using such interferon-associated antigen binding proteins or nucleic acids or expression vectors or pharmaceutical compositions. Said novel interferon-associated antigen binding proteins afford beneficial improvements over the current state of the art, for example in that they effectively disrupt viral replication and thereby reduce HBV viral load.

The present disclosure provides methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a multi-kinase inhibitor.

The present disclosure provides methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a multi-kinase inhibitor.

Combination therapies for the treatment of cancers are provided. In some embodiments, a flagellin derivative such as CBLB502 is administered in combination with an immune checkpoint therapy (e.g., an anti-PD 1 antibody and an anti-CTLA4 antibody) to treat a cancer in a mammalian subject. In some embodiments, the combination therapy is administered intratumorally or peritumorally.

Combination therapies for the treatment of cancers are provided. In some embodiments, a flagellin derivative such as CBLB502 is administered in combination with an immune checkpoint therapy (e.g., an anti-PD 1 antibody and an anti-CTLA4 antibody) to treat a cancer in a mammalian subject. In some embodiments, the combination therapy is administered intratumorally or peritumorally.

The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes TIGIT. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen-binding fragment thereof.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

The present invention provides compositions and methods for down-modulating the expression and/or the immuno-suppressive activity of i) the FMRP protein, ii) an mRNA encoding the FMRP protein, and/or iii) the FMR1 gene for the treatment and/or prevention of primary cancer and/or cancer metastasis in a subject in need thereof.